Medicon Valley Biomedical Newsletter

7TM Pharma A/S has initiated a Phase II clinical study of Obinepitide, which is being developed for the treatment of obesity and related diseases. The drug candidate is a close analogue of two natural...

7TM Pharma A/S has raised EUR 16.5 million in a new financing round. The financing round included SR One Limited, SR One, who led the investment with strong support from the company's existing inv...

ACADIA Pharmaceuticals Inc. has announced the initiation of its first Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson's disease psychosis,...

Active Biotech AB and Teva Pharmaceutical Industries Ltd. have announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomo...

Agnitio A/S has announced the opening of a new sales office in Germany which allows Agnitio to improve its service offering to both new and existing clients and partners in the German market. ...

Alligator Bioscience AB has announced that it has raised an additional EUR 1.14 million in a second closing of the round of equity financing. The second closing totals the financing round at EUR 6.6 m...

The U.S. Department of Health and Human Services has awarded a contract to Bavarian Nordic A/S for the manufacture and delivery of 20 million doses of the company's MVA based smallpox vaccine, IMV...

CellaVision AB has been admitted to trading on First North by the OMX Nordic Exchange. Since launching its first products in 2001, CellaVision, which develops and sells image based products for...

Researchers from Copenhagen University and Statens Serum Institute headed by professor Ulla Wewer and consultant Michael Christiansen have developed a test that can reveal from a blood sample early in...

Exiqon A/S has been listed on the Copenhagen Stock Exchange in May 2007. The initial public offering of 8,690,000 shares in Exiqon A/S was met with strong investor interest in Denmark and abroad. The ...

Genmab A/S has announced the initiation of a Phase II study of ofatumumab, HuMax-CD20, in combination with cyclophosphamide, doxorubicin, vincristine and prednisone, CHOP, in patients with previously ...

Genmab A/S has announced that the company will become a member of the Copenhagen Stock Exchange's OMXC20 index. The index is comprised of the 20 most actively traded shares on the Copenhagen Stock Exc...

H. Lundbeck A/S and BioTie Therapies Corp. has announced that the licensing agreement has entered into force on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, an...

LifeCycle Pharma A/S has announced an initiation of a Phase II clinical trial program using LCP-Tacro to prevent organ rejection in kidney transplant patients. The clinical trial protocol has been rev...

MediCult has successfully closed the acquisition of US based Humagen Fertility Diagnostics Inc. Humagen is the world's leading supplier of micropipets used in IVF procedures. The acquisition means...

Novo Nordisk A/S and Neose Technologies, Inc. have announced that Novo Nordisk has initiated a Phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of NovoSeven Coagulation Fact...

Novo Nordisk A/S has opened its EUR 74 million, 200,000 square-foot expanded facility in Clayton, North Carolina, US, to meet the country's increasing demand for FlexPen, the world's number on...

Novozymes has opened a new office in Washington D.C. The office is located at the Danish embassy in Washington, D.C. The purpose is to create new and improve existing contacts with decision makers wit...

Nycomed's investigational surfactant product Venticute, rSP-C- Surfactant, has been granted "Fast Track" designation by the United States Food and Drug Administration for reduction of mo...